Molecular Imaging, Inc.

Molecular Imaging Inc. is the only Contract Research Organization (CRO) dedicated to providing small animal in vivo multi-modality imaging services (anatomical, functional, molecular). The combination and depth of experience in our pharmacology and imaging teams is what makes us different and a valued partner to the pharmaceutical industry.

Imaging modalities currently include small animal MRI, PET , CT, bioluminescence, fluorescence, FMT, DEXA, 2D X-ray and in the near future we will be adding many exciting new modalities. Molecular Imaging offers pharmacology models primarily in support of Oncology and Inflammation research. We are also rapidly expanding the number of models available across a range of therapeutic areas through our own R&D program and in collaboration with our clients.

With nearly a decade of CRO imaging experience, Molecular Imaging combines broad protocol and model validation, optimized image acquisition and analysis throughput, with strong client-oriented project management.

Check back soon for our new website or contact us now to speak with one of our experts.

News

View on demand Science Magazine Webinar from December 7th entitled "Determining the Impact of New Therapeutic Approaches - Advancing Imaging in Animals."
Speakers: Dr Mathias Nahrendorf of Harvard Medical School and Dr Patrick McConville, Chief Scientific Officer Molecular Imaging
Follow link to register www.sciencemag.org/webinar

Molecular Imaging, Inc. Enters Relationship with Dana-Farber Cancer Institute to Expand Luciferase-reporter Cancer Cell Lines for Preclinical in vivo Imaging. Download the press release.